Impact of Relative Dose Intensity of FOLFOX Adjuvant Chemotherapy on Risk of Death Among Stage III Colon Cancer Patients

Research on optimal relative dose intensity (RDI) of FOLFOX in stage III colon cancer by risk profiles is scarce. Using cancer registries’ data, our study found when the risk of death remained the same, the minimum RDI of FOLFOX was as low as 70% for high-risk stage III colon cancer patients and as...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Meijiao, Thompson, Trevor D., Lin, Hui-Yi, Chen, Vivien W., Karlitz, Jordan J., Fontham, Elizabeth T.H., Theall, Katherine P., Zhang, Lu, Hsieh, Mei-Chin, Pollack, Lori A., Wu, Xiao-Cheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8971135/
https://www.ncbi.nlm.nih.gov/pubmed/34756680
http://dx.doi.org/10.1016/j.clcc.2021.09.008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8971135/
https://www.ncbi.nlm.nih.gov/pubmed/34756680
http://dx.doi.org/10.1016/j.clcc.2021.09.008

Ejemplares similares